List of Nature Research journals

Artificial intelligence identifies anti-aging drug candidates targeting ‘zombie’ cells

Retrieved on: 
Thursday, May 4, 2023
Health, Biotechnology, Biomedical engineering, Nobel Prize, Nobel Prize in Chemistry, Institute for Medical Engineering and Science, Human, Broad Institute, McMillan, Nature, Hemolysis, Diabetes, Cardiovascular disease, Ageing, Cancer, Intelligence, Multimedia, Research, Medicine, MIT, Inflammation, Cell, Harvard University, Massachusetts Institute of Technology, Fibrosis, Biology, Machine learning, Apoptosis, Bâtiment des Forces motrices, Drug discovery, Conscience, Mouse, Artificial intelligence, AI, Longevity, Notifiable disease, Princeton University, Synthetic biology, Senolytic, Pharmaceutical industry, Science, List of Nature Research journals, Chemistry

View the full release here: https://www.businesswire.com/news/home/20230504005270/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20230504005270/en/
    Senolytics are an emerging class of investigational drug compounds that selectively kill aging-associated senescent cells (left, with red stain) without affecting other cells (right).
  • Using artificial intelligence, researchers from Integrated Biosciences have, for the first time, identified three senolytics with comparable efficacy and superior drug-like properties relative to leading investigational compounds.
  • (Photo: Business Wire)
    “This research result is a significant milestone for both longevity research and the application of artificial intelligence to drug discovery,” said Felix Wong, Ph.D., co-founder of Integrated Biosciences and first author of the publication.
  • Integrated Biosciences was founded in 2022 to overcome these obstacles, target other neglected hallmarks of aging, and advance anti-aging drug development more generally using artificial intelligence, synthetic biology and other next-generation tools.

Elysium Health™ Announces Addition of Nine Systems to Leading Biological Age Test INDEX™ Alongside Launch of Aging Research Center by Elysium Health™

Retrieved on: 
Wednesday, February 15, 2023
Elysium, Happiness, Woman, Elysium Health, Health, Fertility, Diet, Blood, MIT, Epidemiology, Sleep, Nursing, Nurses' Health Study, Harvard University, Liver, Harvard T.H. Chan School of Public Health, Coronavirus Scientific Advisory Board, Inflammation, Research, Male, Female, INDEX, Heart, Disease, Loneliness, Public health, Machine learning, Cardiovascular disease, AI, Cancer, Kidney, Longevity, Pharmaceutical industry, Ageing, Index, List of Nature Research journals

NEW YORK, Feb. 15, 2023 /PRNewswire/ -- Elysium Health, Inc.™, a leading life sciences company focused on aging, today announced the addition of nine new measures of aging to its leading biological age test INDEX™ alongside the launch of the Aging Research Center by Elysium Health, both of which are firsts in the longevity field. Already the most precise biological age test available compared to other published epigenetic measures of aging, and utilizing superior technology demonstrated in Nature Aging, Index now measures the ages of nine systems–brain, liver, metabolic, immune, heart, hormone, kidney, inflammation, and blood. Elysium Health is pleased to be the first company to offer this level of novel in-depth insight.

Key Points: 
  • NEW YORK, Feb. 15, 2023 /PRNewswire/ -- Elysium Health, Inc.™, a leading life sciences company focused on aging, today announced the addition of nine new measures of aging to its leading biological age test INDEX ™ alongside the launch of the Aging Research Center by Elysium Health, both of which are firsts in the longevity field.
  • The study of epigenetics is at the forefront of research in the field of aging, and biological age is becoming a leading standard to measure overall health and wellness.
  • Through collaboration with the Elysium community, the Aging Research Center will provide consumers with the first-ever opportunity to participate directly in longevity research, enabling greater public access to breakthroughs in the field.
  • The Aging Research Center will debut with a landmark prospective aging study–the Translational Initiative to Map Epigenetics in Aging (TIME-A).

Nutrition leaders urge scale-up of new intervention to prevent child malnutrition and mortality

Retrieved on: 
Thursday, February 9, 2023
USAID, University of California, Davis, Diet, Wasting, Nutrient, Vitamin A, Family, Iron deficiency, Failure, Life, Child, World Food Programme, COVID-19, Malnutrition, F-100 and F-75 (foods), Bill, Survival, UNICEF, Poverty, University, Nutrition, Food, International development, Hunger, Appetite, Growth, Mortality, Vitamin, Mother, United States Agency for International Development, Bill & Melinda Gates Foundation, Death, World Bank, Dietary supplement, List of Nature Research journals

In addition to breastmilk, infants and toddlers require nutrient-rich diets to support their rapid growth and development.

Key Points: 
  • In addition to breastmilk, infants and toddlers require nutrient-rich diets to support their rapid growth and development.
  • Yet globally, less than 30% of children ages 6 to 23 months consume a diet that meets the minimum diversity of food groups needed.
  • The failure to provide adequate nutrition in the first two years of life has drastic consequences, as undernutrition is an underlying cause of 45% of deaths among young children.
  • Used to enrich the diets of children 6-23 months of age, small-quantity lipid-based nutrient supplements would help children facing undernutrition survive and thrive.

Indigenous territories and protected areas are key to forest conservation in the Brazilian Amazon, study shows

Retrieved on: 
Friday, January 6, 2023
Research, Coordination of the Indigenous Organizations of the Brazilian Amazon, COVID-19, OU, Multimedia, University, Amazon, Amazônia Legal, Forest, Agriculture, List of Nature Research journals

NORMAN, Okla., Jan. 6, 2023 /PRNewswire/ -- A U.S.-Brazilian study led by the University of Oklahoma reveals the vital role of Indigenous territories and protected areas in forest conservation in the Brazilian Amazon.

Key Points: 
  • NORMAN, Okla., Jan. 6, 2023 /PRNewswire/ -- A U.S.-Brazilian study led by the University of Oklahoma reveals the vital role of Indigenous territories and protected areas in forest conservation in the Brazilian Amazon.
  • Rebuilding effective governmental conservation policies is vital to reducing forest area loss in the Brazilian Amazon.
  • Since 2000, Indigenous territories and protected areas have increased substantially in the Brazilian Amazon and by 2013, Indigenous territories and protected areas accounted for 43% of the total land area and covered approximately 50% of the total forest area.
  • "This finding highlights the vital role of Indigenous territories and the protected areas for forest conservation in the region."

PureTech’s LYT-300 (Oral Allopregnanolone) Demonstrates Oral Bioavailability, Tolerability and GABAA Receptor Target Engagement in Healthy Volunteers

Retrieved on: 
Monday, December 19, 2022
Biotechnology, FDA, Health, Pharmaceutical, Clinical Trials, Lymphatic system, PAM, Annual report, Patient, U.S. FDA, Journal of the Neurological Sciences, Monash University, Benzodiazepine, University of Melbourne, Disorder, Liver, Immune system, Journal, Environment, Depression, Evaluation, Angewandte Chemie, Kathryn Bullock, PRTC, Drug development, Pharmacy, Allopregnanolone, FDA, Safety, Clinical trial, PPD, LSE, CDER, GABA, Multimedia, Fat, Food, PureTech Health, Pharmacology, Parkinson's disease, Monash Institute of Medical Research, Therapy, Journal of Controlled Release, Platform supply vessel, GABAA, Research, Control, Pharmaceutical industry, Vaccine, CBD, Glyph, List of Nature Research journals

View the full release here: https://www.businesswire.com/news/home/20221219005209/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20221219005209/en/
    PureTech announced topline results for LYT-300 (oral allopregnanolone), a therapeutic candidate in development for neurological and neuropsychological conditions.
  • The results show that oral administration of LYT-300 achieved blood levels of allopregnanolone at or above those associated with therapeutic benefit and results in exposure-dependent target engagement of GABAA receptors.
  • The impact of LYT-300 on b-EEG and other markers of GABAA target engagement were also assessed.
  • PureTech completed a Phase 1 clinical trial of LYT-300 in 2022, which demonstrated oral bioavailability, tolerability and GABAA receptor target engagement in healthy volunteers.

CinCor Pharma Announces Publication of Phase 1 Multiple Ascending Dose Study Data in Hypertension Research

Retrieved on: 
Friday, October 21, 2022
Time, Hypertension, Risk, SEC, Population, Achievement, Stroke, MAD, Annual report, NASDAQ, Patient, Degenerative disease, List of Nature Research journals, Primary aldosteronism, Aldosterone, Kidney disease, Pharmacokinetics, Death, Research, Adult, Safety, American Heart, CINC, GLOBE, Plasma, American College, Manuscript, COVID-19, Half-life, Pharmaceutical industry, Collection

WALTHAM, Mass., Oct. 21, 2022 (GLOBE NEWSWIRE) -- CinCor Pharma, Inc. (NASDAQ: CINC) today announced the publication of Phase 1 clinical data for baxdrostat, a highly selective, once daily, oral small molecule inhibitor of aldosterone synthase, in the journal Hypertension Research.

Key Points: 
  • WALTHAM, Mass., Oct. 21, 2022 (GLOBE NEWSWIRE) -- CinCor Pharma, Inc. (NASDAQ: CINC) today announced the publication of Phase 1 clinical data for baxdrostat, a highly selective, once daily, oral small molecule inhibitor of aldosterone synthase, in the journal Hypertension Research.
  • The publication includes clinical data from the companys randomized, Phase 1, placebo controlled multiple ascending dose (MAD) study evaluating the safety, pharmacokinetics, and pharmacodynamics of baxdrostat in healthy volunteers.
  • The dose-dependent reduction in plasma aldosterone and lack of impact on cortisol reinforce the selective blockade of aldosterone synthase by baxdrostat.
  • We believe these proof-of-concept data support further clinical advancement of this promising new treatment for hypertension, said Mason Freeman, M.D., Chief Medical Officer at CinCor.

CGTN: China to continue green transition toward carbon peak and neutrality

Retrieved on: 
Friday, October 21, 2022
Belt, BRI, Sustainable development, List of Nature Research journals, United Nations General Assembly, National Congress of the Chinese Communist Party, Coal, Policy, NASA, Paris, Paris Agreement, Carbon, Research, Communist party, History, Goal, GDP, CPC, Environment, United Nations, Hydra, Climate change, Wind, Boston University, Silk Road, National Congress, Solution, Renewable energy, Fossil fuel, Agriculture, Ecology

BEIJING, Oct. 21, 2022 /PRNewswire/ --China will actively implement its policies to work toward the goals of reaching peak carbon emissions by 2030 and carbon neutrality by 2060, Vice Minister of Ecology and Environment Zhai Qing said Friday.

Key Points: 
  • BEIJING, Oct. 21, 2022 /PRNewswire/ --China will actively implement its policies to work toward the goals of reaching peak carbon emissions by 2030 and carbon neutrality by 2060, Vice Minister of Ecology and Environment Zhai Qing said Friday.
  • "As the world's largest developing country, China will make the world's biggest cut in carbon emission intensity, and move from carbon peak to carbon neutrality in the shortest time in history, which fully demonstrates the country's sense of responsibility as a big country," he noted.
  • To achieve the goals, China will accelerate the low-carbon transition in key areas and vigorously push the synergy of pollution reduction and carbon cut, Zhai said.
  • Heading forward, China will work with all parties to actively participate in the global governance of climate change.

CGTN: China to continue green transition toward carbon peak and neutrality

Retrieved on: 
Friday, October 21, 2022
Belt, BRI, Sustainable development, List of Nature Research journals, United Nations General Assembly, National Congress of the Chinese Communist Party, Coal, Policy, NASA, Paris, Paris Agreement, Carbon, Research, Communist party, History, Goal, GDP, CPC, Environment, United Nations, Hydra, Climate change, Wind, Boston University, Silk Road, National Congress, Solution, Renewable energy, Fossil fuel, Agriculture, Ecology

BEIJING, Oct. 21, 2022 /PRNewswire/ --China will actively implement its policies to work toward the goals of reaching peak carbon emissions by 2030 and carbon neutrality by 2060, Vice Minister of Ecology and Environment Zhai Qing said Friday.

Key Points: 
  • BEIJING, Oct. 21, 2022 /PRNewswire/ --China will actively implement its policies to work toward the goals of reaching peak carbon emissions by 2030 and carbon neutrality by 2060, Vice Minister of Ecology and Environment Zhai Qing said Friday.
  • "As the world's largest developing country, China will make the world's biggest cut in carbon emission intensity, and move from carbon peak to carbon neutrality in the shortest time in history, which fully demonstrates the country's sense of responsibility as a big country," he noted.
  • To achieve the goals, China will accelerate the low-carbon transition in key areas and vigorously push the synergy of pollution reduction and carbon cut, Zhai said.
  • Heading forward, China will work with all parties to actively participate in the global governance of climate change.

Staying on Top of the Roof of the World

Retrieved on: 
Friday, October 14, 2022
Ohio State University, Ecology, University of Gothenburg, CAS, Byrd Polar and Climate Research Center, FPS, International Symposium on Graph Drawing, Comment, Carbon, Research, UNESCO, Program, Institute, STEP, UNEP, Knowledge, University, List of Nature Research journals, Hydrology, TPE, Survival, Environment, Climate change, SCOPE, Water resources, Chinese Academy of Sciences, Antarctic, Arctic

They were later joined by Deliang Chen from Sweden and PIAO Shilong from China.

Key Points: 
  • They were later joined by Deliang Chen from Sweden and PIAO Shilong from China.
  • "Ice core records and tree ring records can also be compared to further calibrate our understanding of Earth's history," he added.
  • In his latest NREEreview article , Yao reported STEP findings that water storage in the region has been knocked off balance by climate change.
  • "For more accurate prediction, we are integrating our understanding of individual processes into a modelling framework covering various spatial scales."

Gradalis Announces Publication of Two Studies Demonstrating the Positive Results of Vigil® in Combination with Checkpoint Inhibitors

Retrieved on: 
Monday, October 3, 2022
Clinical Medicine Insights: Oncology, Phase 1, Cancer, GLOBE, Toxicity, RFS, Trifecta, Neoplasm, PFS, VITAL, Combination, Immunotherapy, Randomized controlled trial, Research, Clinical trial, Relapse, HRP, Population, OS, AstraZeneca, TNBC, List of Nature Research journals, Immune system, Safety, GameChanger, Breast cancer, Large-cell lung carcinoma, Epitope, Patient, PD-L1, The Lancet, American Society of Clinical Oncology, Ovary, Medicine, DNA, Society, GM, Ovarian cancer, BRCA, Pharmaceutical industry, Medical imaging, Vaccine, DALLAS, Woman, Durvalumab

DALLAS, Oct. 03, 2022 (GLOBE NEWSWIRE) -- Gradalis, Inc., a privately held, late-stage clinical biotechnology company, today announced a peer-reviewed publication in Clinical Medicine Insights: Oncology demonstrating positive results from a pilot study investigating Vigil® in combination with a PD-L1 checkpoint inhibitor, durvalumab (Imfinzi® - AstraZeneca), in patients with advanced triple negative breast cancer (TNBC) or recurrent/refractory ovarian cancer (OC). This study also suggests that administration of Vigil with durvalumab improved progression free survival (PFS) in patients with PD-L1 positive tumors compared to those with PD-L1 negative tumors.

Key Points: 
  • Vigil is the first cellular immunotherapy to demonstrate survival benefits in a randomized controlled trial of patients with solid tumors.
  • John Nemunaitis, M.D., Chief Scientific Officer of Gradalis commented, These two clinical trials underscore the therapeutic utility of combining Vigil and checkpoint inhibitors without generating incremental toxicity relative to that shown with single agent checkpoint inhibitor therapy.
  • Vigil in combination with durvalumab demonstrated no grade 3 or greater adverse events that were attributed to Vigil by the investigators.
  • Vigil is being studied in other cancer types and has shown positive results in combination with checkpoint inhibitors.